Repository

Publications

Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population

Prinzi FL, Salani F, Camera S, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Gallio C, Tamberi S, Finkelmeier F, Giordano G, Chiara P, Chon HJ, Braconi C, Qaisar A, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Couto N, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Polito MG, Di Giacomo E, Farinea G, Bartalini L, Grelli G, De Rosa A, Lavacchi D, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Tesini G, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Bekaii-Saab T, Fornaro L, Masi G, Vogel A, Lonardi S, Rimini M, Rimassa L, Casadei-Gardini A.
Int J Cancer . 2025 Nov 15;157(10):2092-2102. doi: 10.1002/ijc.70009
2025 
Result from  

The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population

Rimini M, Fornaro L, Lo Prinzi F, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Jae Chon H, Braconi C, Qaisar A, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Corallo S, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Farinea G, Salani F, De Rosa A, Lavacchi D, Camera S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Zanuso V, Malapelle U, Pepe F, Masi G, Vogel A, Lonardi S, Rimassa L, Casadei-Gardini A.
J Natl Cancer Inst . 2025 Oct 1;117(10):2029-2043. doi: 10.1093/jnci/djaf155
2025 
Result from  

Targeting EIF4A1 is effective against human intrahepatic cholangiocarcinoma

Mi W, Cigliano A, Galleri G, Gigante I, Steinmann SM, Cibali E, Serra M, Pes GM, Schloesser D, Pizzuto E, Siegmund H, Fischer C, Saborowski A, Giannelli G, Evert M, Wilhelmus van der Laan LJ, Verstegen MMA, Calvisi DF
JHEP Rep. 2025 Apr 3;7(7):101416. doi: 10.1016/j.jhepr.2025.101416
2025 
Result from  

From barriers to solutions: an expert-based algorithm for cholangiocarcinoma and other biliary tract cancers testing in the Era of precision oncology

Stenzinger A, Normanno N, Lamarca A, Rimassa L, Bibeau F, Taniere P, Vogel A, Hollebecque A.
Expert Rev Mol Diagn . 2025 Aug;25(8):495-508. doi: 10.1080/14737159.2025.2521538
2025 
Result from  

A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D Index

Persano M, Rimini M, Salani F, Prinzi FL, Nichetti F, Saborowski A, Antonuzzo L, Passeri L, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Corallo S, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Qaisar A, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Couto N, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Farinea G, Fornaro L, De Rosa A, Lanzetta I, Balsano R, Lavacchi D, Camera S, Ikeda M, Dekervel J, Niger M, Tesini G, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Ferrara M, Himmelsbach V, Landriscina M, Djaballah SA, Masi G, Vogel A, Lonardi S, Rimassa L, Casadei-Gardini A.
Liver Int. 2025 Jul;45(7):e70181. doi: 10.1111/liv.70181.
2025 
Result from  
Join the Action
JOIN